52 results  1 of 3 

1 Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation
Jieun Uhm
Blood Res.2023;58(S1):S109-S113.   Published online 2023 April 30     DOI: http://dx.doi.org/10.5045/br.2023.2023054
      
2 Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
Jae Joon Han
Blood Res.2023;58(S1):S58-S65.   Published online 2023 April 7     DOI: http://dx.doi.org/10.5045/br.2023.2023035
      
3 EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
Weiguang Gu, Hua Zhang, Yiyu Lu, Minjing Li, Shuang Yang, Jianmiao Liang, Zhijian Ye, Zhihua Li, Minhong He, Xiaoliang Shi, Fei Wang, Dong You, Weiquan Gu, Weineng Feng
Cancer Res Treat.2023;55(3):841-850.   Published online 2023 February 13     DOI: http://dx.doi.org/10.4143/crt.2022.1438
      
4 Clinical Impact of Drug Adherence of Tyrosine Kinase Inhibitors in Children with Ph-Positive Acute Lymphoblastic Leukemia
Jun-Xia Wang, Miao-Miao Yang, Li-Peng Liu, Hui-Min Zhang, Meng-Chuan Wang, Yu-Wen Chen, Xiao-Ying Zang, Fang Hu
Cancer Res Treat.2023;55(3):1023-1030.   Published online 2023 February 6     DOI: http://dx.doi.org/10.4143/crt.2022.1618
      
5 Effect of Afatinib for Lung Cancer on Papillary Thyroid Carcinoma
Sang Hwon Cho, Jin Seok Lee, Hyeok Jun Yun, Yong Sang Lee, Hang-Seok Chang
Int J Thyroidol.2022;15(2):131-134.   Published online 2022 November 30     DOI: http://dx.doi.org/10.11106/ijt.2022.15.2.131
      
6 Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea
Seo-Yeon Ahn, Sang Kyun Son, Gyu Hyung Lee, Inho Kim, June-Won Cheong, Won Sik Lee, Byung Soo Kim, Deog-Yeon Jo, Chul Won Jung, Chu Myoung Seong, Jae Hoon Lee, Young Jin Yuh, Min Kyoung Kim, Hun-Mo Ryoo, Moo-Rim Park, Su-Hee Cho, Hoon-Gu Kim, Dae Young Zang, Jinny Park, Hawk Kim, Seryeon Lee, Sung-Hyun Kim, Myung Hee Chang, Ho Sup Lee, Chul Won Choi, Jihyun Kwon, Sung-Nam Lim, Suk-Joong Oh, Inkyung Joo, Dong-Wook Kim
Blood Res.2022;57(2):144-151.   Published online 2022 June 30     DOI: http://dx.doi.org/10.5045/br.2022.2021137
      
7 Lung Related Complications in Patients with Advanced Thyroid Cancer during Lenvatinib Therapy: Case Series and Literature Review
Jee Hee Yoon, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
Int J Thyroidol.2022;15(1):42-48.   Published online 2022 May 30     DOI: http://dx.doi.org/10.11106/ijt.2022.15.1.42
      
8 FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs
Jae-Sook Ahn, Hyeoung-Joon Kim
Blood Res.2022;57(S1):32-36.   Published online 2022 April 30     DOI: http://dx.doi.org/10.5045/br.2022.2022017
      
9 Nilotinib-Induced Acute Interstitial Nephritis during the Treatment of Chronic Myeloid Leukemia
Min Jeong Kim
Kosin Med J.2021;36(2):153-160.   Published online 2021 December 31     DOI: http://dx.doi.org/10.7180/kmj.2021.36.2.153
      
10 Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer
Young Kee Shong
Int J Thyroidol.2021;14(2):98-111.   Published online 2021 November 30     DOI: http://dx.doi.org/10.11106/ijt.2021.14.2.98
      
11 The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang
Cancer Res Treat.2022;54(2):434-444.   Published online 2021 August 2     DOI: http://dx.doi.org/10.4143/crt.2021.671
      
12 Real-world management of chronic myeloid leukemia in South Korea: the TARGET survey
Jieun Uhm, Kyoung Ha Kim, Hyewon Lee, Hawk Kim, Slader Cassandra, Inkyung Joo, Chul Won Jung
Blood Res.2021;56(1):31-37.   Published online 2021 January 28     DOI: http://dx.doi.org/10.5045/br.2021.2020260
      
13 Advanced Stage Hepatocellular Carcinoma Successfully Treated with Transarterial Radioembolization and Multi-tyrosine Kinase Inhibitor Therapy
Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
J Liver Cancer.2020;20(2):160-166.   Published online 2020 September 30     DOI: http://dx.doi.org/10.17998/jlc.20.2.160
      
14 EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Sehhoon Park, Bo Mi Ku, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat.2020;52(4):1288-1290.   Published online 2020 June 22     DOI: http://dx.doi.org/10.4143/crt.2020.278
      
15 Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
Ying Lin, Mingxi Lin, Jian Zhang, Biyun Wang, Zhonghua Tao, Yiqun Du, Sheng Zhang, Jun Cao, Leiping Wang, Xichun Hu
Cancer Res Treat.2020;52(4):1059-1066.   Published online 2020 April 24     DOI: http://dx.doi.org/10.4143/crt.2019.633
      
16 RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer
Tian-Hao Weng, Min-Ya Yao, Xiang-Ming Xu, Chen-Yu Hu, Shu-Hao Yao, Yi-Zhi Liu, Zhi-Gang Wu, Tao-Ming Tang, Pei-Fen Fu, Ming-Hai Wang, Hang-Ping Yao
Cancer Res Treat.2020;52(3):973-986.   Published online 2020 April 22     DOI: http://dx.doi.org/10.4143/crt.2019.726
      
17 Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review
Dae Hyun Lim, Jai Hoon Yoon, Dae Won Jun, Oh Young Lee, Byung Chul Yoon, Hang Rak Lee, Kyung Soo Kim, Ho Soon Choi
J Liver Cancer.2020;20(1):67-71.   Published online 2020 March 31     DOI: http://dx.doi.org/10.17998/jlc.20.1.67
      
18 Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma
Hee Sang Hwang, Yun-Yong Park, Su-Jin Shin, Heounjeong Go, Ja-Min Park, Sun Young Yoon, Jae-Lyun Lee, Yong Mee Cho
J Korean Med Sci.2020;35(5):e31.  Published online 2020 January 6     DOI: http://dx.doi.org/10.3346/jkms.2020.35.e31
      
19 Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
Myung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, Byoung Chul Cho, Jin-Hyoung Kang, Sang-We Kim, James Chih-Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee
Cancer Res Treat.2020;52(1):284-291.   Published online 2019 July 23     DOI: http://dx.doi.org/10.4143/crt.2019.200
      
20 Management of Bleeding Induced by Tyrosine Kinase Inhibitor in Radioiodine Refractory Thyroid Cancer
Dong Yeob Shin
Int J Thyroidol.2018;11(2):71-74.   Published online 2018 November 30     DOI: http://dx.doi.org/10.11106/ijt.2018.11.2.71
      

 1 of 3